Research & Development
Small Cell Lung Cancer
New gene target discovered for aggressive small-cell lung cancer subtype
The research team plans to develop a drug to disrupt the functioning of the POU2AF2 gene. Furthermore, because of POU2AF2’s specificity to the subtype, it may serve as a biomarker, leading to earlier diagnosis.
October 10, 2022
Foundation to present on genomic profiling at ESMO 2022
At the congress, which is being held in Paris September 9-13, Foundation Medicine will highlight the following:
September 6, 2022
Thermo Fisher launches NGS test, software for clinical labs
Using targeted NGS technology, the Oncomine Dx Express Test delivers clinically relevant tumor mutation profiling in 24 hours to aid healthcare professionals in therapy management of cancer patients in accordance with professional guidelines, Thermo Fisher said.
August 29, 2022
Thermo Fisher, Guardant Health get approval for NSCLC CDx
Enhertu is an HER2-directed antibody drug conjugate being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.
August 11, 2022
Foundation Medicine highlights lung cancer study results
The findings are from the Prospective Clinicogenomic (PCG) study and were published August 5 in the Journal of Thoracic Oncology Clinical and Research Reports.
August 7, 2022
Biodesix touts VeriStrat test results
The blood-based test was predictive of progression-free survival and overall survival in patients with non-small cell lung cancer with low or negative PD-L1 treated with immune checkpoint inhibitors, the firm said.
July 19, 2022
BillionToOne launches liquid biopsy products for research
The products are available for research use in select academic cancer centers.
July 7, 2022
Biocartis, AstraZeneca to develop CDx for EGFR TKI treatment
The firms aim to obtain applicable premarket notification or approval from the U.S. Food and Drug Administration (FDA) for a CDx test on Biocartis' fully automated molecular Idylla platform.
June 21, 2022
Foundation Medicine gets FDA nod for NSCLC CDx
Rozlytrek is a targeted therapy for the treatment of non-small cell lung cancer (NSCLC) developed by Roche's Genentech.
June 8, 2022
Stilla and Promega sign comarketing agreement
The companies have combined Promega's Maxwell liquid biopsy system and Stilla's naica system, a six-color multiplexing digital PCR platform. The pairing enables an optimized workflow for a wide range of applications, including liquid biopsy, sentinel pathogen testing, infectious disease assays, overall cancer research, and drug discovery, according to the vendors.
April 7, 2022
Guardant wins new clearances in Japan for liquid biopsy test
The MHLW has cleared Guardant360 CDx for mutation profiling in patients with advanced solid tumors. In addition, it approved Guardant360 CDx as a companion diagnostic for identifying patients with microsatellite instability-high solid tumors who may benefit from pembrolizumab (Keytruda). What's more, Guardant360 CDx has also been approved for patients with MSI-High advanced colorectal cancer who may benefit from nivolumab (Opdivo).
March 14, 2022
Insightec to launch new trials of Exablate Neuro
One study will evaluate the use of Exablate Neuro to treat patients with primary non-small cell lung cancer that has metastasized to the brain in conjunction with Keytruda, a humanized antibody immunotherapy. Exablate Neuro could be used to open up the blood-brain barrier to make immunotherapy agents like Keytruda more effective.
March 9, 2022
Page 1 of 4